We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+12.48%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.36B
AUM Growth
+$152M
Cap. Flow
+$32.9M
Cap. Flow %
1.4%
Top 10 Hldgs %
88.9%
Holding
41
New
11
Increased
4
Reduced
4
Closed
11

Top Buys

Rank Stock Value
1
AKTS
Aktis Oncology
AKTS
+$93.7M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$73.8M
3
CGON icon
CG Oncology
CGON
+$18.7M
4
RLAY icon
Relay Therapeutics
RLAY
+$17M
5
ERAS icon
Erasca
ERAS
+$10.6M

Top Sells

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$61.3M
2
MBX
MBX Biosciences
MBX
+$45.8M
3
GPCR icon
Structure Therapeutics
GPCR
+$23.3M
4
PCVX icon
Vaxcyte
PCVX
+$20.8M
5
AQST icon
Aquestive Therapeutics
AQST
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.22%
2 Miscellaneous 0.7%
3 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRLD icon
26
Prelude Therapeutics
PRLD
$437M
$3.24M 0.14%
+947,049
New +$2.48M
IBIO icon
27
iBio
IBIO
$67.6M
$3.01M 0.13%
1,583,000
-645,000
-29% -$1.5M
HLXC
28
Helix Acquisition Corp III
HLXC
$238M
$2.03M 0.09%
+200,000
New +$2.05M
ATRA icon
29
Atara Biotherapeutics
ATRA
$92.3M
$471K 0.02%
99,593
-473,590
-83% -$2.89M
SRZNW
30
DELISTED
Surrozen Inc Warrant
SRZNW
$129K 0.01%
4,444
– –
AQST icon
31
Aquestive Therapeutics
AQST
$630M
– –
-2,625,000
Closed -$17M
CAMP icon
32
CAMP4 Therapeutics
CAMP
$260M
– –
-325,000
Closed -$1.99M
CGON icon
33
CALL
CG Oncology
CGON
$6.59B
– –
-292,800
Closed -$12.2M
EOLS icon
34
Evolus
EOLS
$587M
– –
-675,000
Closed -$4.49M
GPCR icon
35
Structure Therapeutics
GPCR
$3.38B
– –
-334,380
Closed -$23.3M
IMNM icon
36
Immunome
IMNM
$3.13B
– –
-2,855,590
Closed -$61.3M
MNKD icon
37
MannKind Corp
MNKD
$1.27B
– –
-1,660,000
Closed -$9.41M
NUVB.WS
38
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
– –
-963,333
Closed -$8.63M
PCVX icon
39
Vaxcyte
PCVX
$8.9B
– –
-450,000
Closed -$20.8M
VYGR icon
40
Voyager Therapeutics
VYGR
$218M
– –
-4,002,847
Closed -$15.7M
XNCR icon
41
CALL
Xencor
XNCR
$1.94B
– –
-67,500
Closed -$1.03M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2026 Portfolio in Review

As of Q1 2026, EcoR1 Capital held 41 positions worth $2.36B, up 6.9% from $2.2B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

EcoR1 Capital's Q1 2026 filing shows 11 new, 4 increased, 4 reduced and 11 closed positions. Its largest new stake was Aktis Oncology: 4,824,469 shares worth $86.3M. The largest sale was Immunome, an estimated $61.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

  • EcoR1 Capital's largest Q1 2026 buy was Aktis Oncology: 4,824,469 shares worth $86.3M.
  • EcoR1 Capital added most to Centessa Pharmaceuticals in Q1 2026, an estimated $73.8M increase.
  • EcoR1 Capital's biggest Q1 2026 reduction was MBX Biosciences, cutting an estimated $45.8M.
  • EcoR1 Capital fully exited Immunome in Q1 2026, selling an estimated $61.3M.
  • EcoR1 Capital's ten largest holdings make up 89% of its $2.36B portfolio in Q1 2026.
  • EcoR1 Capital opened 11 new positions and closed 11 in Q1 2026.
  • EcoR1 Capital's portfolio value rose 6.9% quarter-over-quarter to $2.36B.

Based on EcoR1 Capital's 13F filing for Q1 2026, filed 15 May 2026.